|
 |
|
|||||||
|
|||||||||
© 2003 by the American Diabetes Association, Inc.
Emerging Treatments and Technologies |
The Sensory Symptoms of Diabetic Polyneuropathy Are Improved With 
-Lipoic Acid
The SYDNEY Trial
The SYDNEY Trial Authors, for the SYDNEY Trial Study Group:
1 Russian Medical Academy for Advanced Studies, Moscow, Russia
2 Neurology Clinic, Moscow Medical Academy, Russia
3 Mayo Clinic, Rochester, Minnesota
4 Viatris GmbH, Frankfurt, Germany
5 Health Partners Medical Group, Minneapolis, Minnesota
6 Ergomed, Zagreb, Croatia
7 German Diabetes Research Institute, University of Düsseldorf, Germany
OBJECTIVE— Because 
-lipoic acid (ALA), a potent antioxidant, prevents or improves nerve conduction attributes, endoneurial blood flow, and nerve (Na(+) K(+) ATPase activity in experimental diabetes and in humans and may improve positive neuropathic sensory symptoms, in this report we further assess the safety and efficacy of ALA on the Total Symptom Score (TSS), a measure of positive neuropathic sensory symptoms.
RESEARCH DESIGN AND METHODS— Metabolically stable diabetic patients with symptomatic (stage 2) diabetic sensorimotor polyneuropathy (DSPN) were randomized to a parallel, double-blind study of ALA (600 mg) (n = 60) or placebo (n = 60) infused daily intravenously for 5 days/week for 14 treatments. The primary end point was change of the sum score of daily assessments of severity and duration of TSS. Secondary end points were sum scores of neuropathy signs (NIS), symptoms (NSC), attributes of nerve conduction, quantitative sensation tests (QSTs), and an autonomic test.
RESULTS— At randomization, the groups were not significantly different by the criteria of metabolic control or neuropathic end points. After 14 treatments, the TSS of the ALA group had improved from baseline by an average of 5.7 points and the placebo group by an average of 1.8 points (P < 0.001). Statistically significant improvement from baseline of the ALA, as compared with the placebo group, was also found for each item of the TSS (lancinating and burning pain, asleep numbness and prickling), NIS, one attribute of nerve conduction, and global assessment of efficacy.
CONCLUSIONS— Intravenous racemic ALA, a potent antioxidant, rapidly and to a significant and meaningful degree, improved such positive neuropathic sensory symptoms as pain and several other neuropathic end points. This improvement of symptoms was attributed to improved nerve pathophysiology, not to increased nerve fiber degeneration. Because of its safety profile and its effect on positive neuropathic sensory symptoms and other neuropathic end points, this drug appears to be a useful ancillary treatment for the symptoms of diabetic polyneuropathy.
Abbreviations: ALA, -lipoic acid • DSPN, diabetic sensorimotor polyneuropathy • HP-DB, heart pulse deep breathing • ITT, intent-to-treat • NIS, neuropathy impairment score • NIS(LL), NIS of lower limbs • NSC, neuropathy symptoms and change • NSC(LL), neuropathy symptoms and change of lower limbs • PP, per protocol • QST, quantitative sensation test • TSS, Total Symptom Score
CiteULike 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  N. W. Milgram, J. A. Araujo, T. M. Hagen, B. V. Treadwell, and B. N. Ames Acetyl-L-carnitine and {alpha}-lipoic acid supplementation of aged beagle dogs improves learning in two landmark discrimination tests FASEB J, November 1, 2007; 21(13): 3756 - 3762. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. G. Obrosova, O. Ilnytska, V. V. Lyzogubov, I. A. Pavlov, N. Mashtalir, J. L. Nadler, and V. R. Drel High-Fat Diet Induced Neuropathy of Pre-Diabetes and Obesity: Effects of "Healthy" Diet and Aldose Reductase Inhibition Diabetes, October 1, 2007; 56(10): 2598 - 2608. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. G. Smith Painful Diabetic Peripheral Neuropathy J Am Podiatr Med Assoc, September 1, 2007; 97(5): 394 - 401. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. S. Foster Efficacy and Safety of {alpha}-Lipoic Acid Supplementation in the Treatment of Symptomatic Diabetic Neuropathy The Diabetes Educator, January 1, 2007; 33(1): 111 - 117. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. R. Drel, N. Mashtalir, O. Ilnytska, J. Shin, F. Li, V. V. Lyzogubov, and I. G. Obrosova The Leptin-Deficient (ob/ob) Mouse: A New Animal Model of Peripheral Neuropathy of Type 2 Diabetes and Obesity Diabetes, December 1, 2006; 55(12): 3335 - 3343. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Ziegler, A. Ametov, A. Barinov, P. J. Dyck, I. Gurieva, P. A. Low, U. Munzel, N. Yakhno, I. Raz, M. Novosadova, et al. Oral Treatment With {alpha}-Lipoic Acid Improves Symptomatic Diabetic Polyneuropathy: The SYDNEY 2 trial. Diabetes Care, November 1, 2006; 29(11): 2365 - 2370. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Schreibelt, R. J. P. Musters, A. Reijerkerk, L. R. de Groot, S. M. A. van der Pol, E. M. L. Hendrikx, E. D. Dopp, C. D. Dijkstra, B. Drukarch, and H. E. de Vries Lipoic Acid Affects Cellular Migration into the Central Nervous System and Stabilizes Blood-Brain Barrier Integrity J. Immunol., August 15, 2006; 177(4): 2630 - 2637. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Yi and N. Maeda {alpha}-Lipoic Acid Prevents the Increase in Atherosclerosis Induced by Diabetes in Apolipoprotein E-Deficient Mice Fed High-Fat/Low-Cholesterol Diet. Diabetes, August 1, 2006; 55(8): 2238 - 2244. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Ilnytska, V. V. Lyzogubov, M. J. Stevens, V. R. Drel, N. Mashtalir, P. Pacher, M. A. Yorek, and I. G. Obrosova Poly(ADP-Ribose) Polymerase Inhibition Alleviates Experimental Diabetic Sensory Neuropathy Diabetes, June 1, 2006; 55(6): 1686 - 1694. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. G. Obrosova, V. R. Drel, P. Pacher, O. Ilnytska, Z. Q. Wang, M. J. Stevens, and M. A. Yorek Oxidative-Nitrosative Stress and Poly(ADP-Ribose) Polymerase (PARP) Activation in Experimental Diabetic Neuropathy: The Relation Is Revisited Diabetes, December 1, 2005; 54(12): 3435 - 3441. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. S. Lee, H. S. Park, S. J. Park, S. R. Kim, K. H. Min, S. M. Jin, K.-H. Park, U.-H. Kim, C. Y. Kim, and Y. C. Lee A Prodrug of Cysteine, L-2-Oxothiazolidine-4-carboxylic Acid, Regulates Vascular Permeability by Reducing Vascular Endothelial Growth Factor Expression in Asthma Mol. Pharmacol., November 1, 2005; 68(5): 1281 - 1290. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Sung, W. Kim, S. Y. Ahn, C.-H. Cho, G. Y. Koh, S.-O. Moon, D. H. Kim, S. Lee, K. P. Kang, K. Y. Jang, et al. Protective Effect of {alpha}-Lipoic Acid in Lipopolysaccharide-Induced Endothelial Fractalkine Expression Circ. Res., October 28, 2005; 97(9): 880 - 890. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Ullian, A. K. Gelasco, W. R. Fitzgibbon, C. N. Beck, and T. A. Morinelli N-Acetylcysteine Decreases Angiotensin II Receptor Binding in Vascular Smooth Muscle Cells J. Am. Soc. Nephrol., August 1, 2005; 16(8): 2346 - 2353. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. F. Corbett Practical Management of Patients With Painful Diabetic Neuropathy The Diabetes Educator, July 1, 2005; 31(4): 523 - 540. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Teichert, T. Tuemmers, H. Achenbach, C. Preiss, R. Hermann, P. Ruus, and R. Preiss Pharmacokinetics of Alpha-Lipoic Acid in Subjects With Severe Kidney Damage and End-Stage Renal Disease J. Clin. Pharmacol., March 1, 2005; 45(3): 313 - 328. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Vincent, J. W. Russell, P. Low, and E. L. Feldman Oxidative Stress in the Pathogenesis of Diabetic Neuropathy Endocr. Rev., August 1, 2004; 25(4): 612 - 628. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J.M. Boulton, R. A. Malik, J. C. Arezzo, and J. M. Sosenko Diabetic Somatic Neuropathies Diabetes Care, June 1, 2004; 27(6): 1458 - 1486. [Full Text] [PDF]
|
|
|
|
 |
|
 R. Bianchi, B. Buyukakilli, M. Brines, C. Savino, G. Cavaletti, N. Oggioni, G. Lauria, M. Borgna, R. Lombardi, B. Cimen, et al. Erythropoietin both protects from and reverses experimental diabetic neuropathy PNAS, January 20, 2004; 101(3): 823 - 828. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Diabetes | Diabetes Care | Clinical Diabetes | Diabetes Spectrum |